Delayed start study of donepezil hydrochloride for cognitive decline in Parkinson's disease following EDAP-1 [EXTENSION OF 700197202]

Trial Profile

Delayed start study of donepezil hydrochloride for cognitive decline in Parkinson's disease following EDAP-1 [EXTENSION OF 700197202]

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Donepezil (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms EDAP-2
  • Most Recent Events

    • 22 Nov 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 24 Jan 2014 Status changed from recruiting to active, no longer recruiting according to University Hospital Medical Information Network-Japan record.
    • 28 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top